The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

4 Dec 2018 13:08

RNS Number : 4088J
Diurnal Group PLC
04 December 2018
 

4 December 2018

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them in accordance with the Market Abuse Regulations

 

On 4 December 2018, Diurnal issued a total of 1,217,259 par value options over ordinary shares of 5 pence in the Company under the Diurnal Group plc Long Term Incentive Plan (the "Plan"), of which the following were issued to persons discharging managerial responsibilities ("PDMR"):

 

PDMR

Total number of shares awarded

Type of awards

Martin Whitaker

255,105

Performance share award

Richard Bungay

204,083

Performance share award

Richard Ross

71,743

 

 

The performance share awards will ordinarily vest no earlier than the third anniversary of their grant subject to the grantee's continued service and to the extent to which the performance conditions set for the awards are satisfied. Such awards may potentially vest until the fifth anniversary of their grant date. The awards were granted under award agreements that incorporated the terms of the Plan. No consideration is due to be payable on vesting.

 

Details of the full notifications received by the Company are set out below:

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Martin Whitaker

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Grant of award of options under the Diurnal Group plc Long Term Incentive Plan over Ordinary shares of 5p each

 

 

Identification code

Ordinary shares: GB00BDB6Q760

 

 

b)

 

Nature of the transaction

 

Grant of awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Performance share award over 255,105 ordinary shares.

 

The performance share award will ordinarily vest no earlier than the third anniversary of its grant subject to continued service and to the extent to which the performance conditions set for the awards are satisfied. Such award may potentially vest until the fifth anniversary of its grant date.

 

No consideration is due to be payable on vesting.

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

Nil exercise price

255,105

 

 

 

 

 

 

d)

 

Aggregated information

 

 

 

- Aggregated volume

Award over 255,105 ordinary shares.

 

 

- Price

Nil price payable for grant and upon exercise

 

 

e)

 

Date of the transaction

 

4 December 2018

f)

 

Place of the transaction

 

Outside a trading venue

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Richard Bungay

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Grant of award of options under the Diurnal Group plc Long Term Incentive Plan over Ordinary shares of 5p each

 

 

Identification code

Ordinary shares: GB00BDB6Q760

 

 

b)

 

Nature of the transaction

 

Grant of awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Performance share award over 204,083 ordinary shares.

 

The performance share award will ordinarily vest no earlier than the third anniversary of its grant subject to continued service and to the extent to which the performance conditions set for the awards are satisfied. Such award may potentially vest until the fifth anniversary of its grant date.

 

No consideration is due to be payable on vesting.

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

Nil exercise price

204,083

 

 

 

 

 

 

d)

 

Aggregated information

 

 

 

- Aggregated volume

Award over 204,083 ordinary shares.

 

 

- Price

Nil price payable for grant and upon exercise

 

 

e)

 

Date of the transaction

 

4 December 2018

f)

 

Place of the transaction

 

Outside a trading venue

 

 

Details of the person discharging managerial responsibilities / person closely associated

 

Name

 

 Richard Ross

Reason for the notification

 

Position/status

 

Chief Scientific Officer

Initial notification /Amendment

 

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

Name

 

Diurnal Group plc

LEI

 

213800I2HNUNZN1LDH29

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

Description of the financial instrument, type of instrument

Grant of award of options under the Diurnal Group plc Long Term Incentive Plan over Ordinary shares of 5p each

 

 

Identification code

Ordinary shares: GB00BDB6Q760

 

 

Nature of the transaction

 

Grant of awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Performance share award over 71,743 ordinary shares.

 

The performance share award will ordinarily vest no earlier than the third anniversary of its grant subject to continued service and to the extent to which the performance conditions set for the awards are satisfied. Such award may potentially vest until the fifth anniversary of its grant date.

 

No consideration is due to be payable on vesting.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

Nil exercise price

71,743

 

 

 

 

 

 

Aggregated information

 

 

 

- Aggregated volume

Award over 71,743 ordinary shares.

 

 

- Price

Nil price payable for grant and upon exercise

 

 

Date of the transaction

 

4 December 2018

Place of the transaction

 

Outside a trading venue

 

 

For further information, please visit www.diurnal.co.uk or contact:

 

 

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer

 

Richard Bungay, Chief Financial Officer

 

 

 

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl

 

Corporate Broking: James Stearns

 

 

 

Cantor Fitzgerald Europe (Joint Broker)

+44 (0)20 7894 7000

Corporate Finance: Phil Davies, Will Goode, Michael Boot

 

Healthcare Equity Sales: Andrew Keith

 

 

 

FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway

 

Victoria Foster Mitchell

 

 

 

Notes to Editors

 

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHFSUFELFASELE
Date   Source Headline
7th Mar 20222:30 pmRNSScottish Medicines Consortium Update
2nd Mar 20227:00 amRNSRegulatory update on oral native testosterone
1st Mar 202210:23 amRNSTotal Voting Rights
24th Feb 202212:00 pmRNSNotice of Interim Results
10th Feb 20227:00 amRNSFirst patient dosed in Phase 2 trial
9th Feb 20227:00 amRNSIssue of Long-Term Incentive Plan awards
1st Feb 20227:00 amRNSTotal Voting Rights
31st Jan 20221:26 pmRNSPostponement of R&D Day
26th Jan 20227:00 amRNSTrading Update
24th Jan 20227:00 amRNSDiurnal to participate in Edison “Open House”
11th Jan 20227:00 amRNSOperational update
7th Jan 202212:58 pmRNSHolding(s) in Company
13th Dec 202112:46 pmRNSBlock Admission Application
2nd Dec 20217:00 amRNSNotice of R&D Day
19th Nov 202111:43 amRNSResults of AGM
16th Nov 20217:00 amRNSAlkindi approved for use in Switzerland
15th Nov 20215:20 pmRNSEton enters into US co-promotion deal
15th Nov 20217:00 amRNSDirectorate Change
8th Nov 20219:16 amRNSHolding(s) in Company
15th Oct 202111:17 amRNSHolding(s) in Company
14th Oct 20217:01 amRNSAppointment of Joint Corporate Broker
14th Oct 20217:00 amRNSAgreement signed with ExCEEd Orphan for CEE
11th Oct 20217:00 amRNSPhase 1 data for DITEST published in EJE
8th Oct 202112:24 pmRNSExercise of Options, Issue of Equity and TVR
7th Oct 202111:15 amEQSHardman & Co Research | Diurnal (DNL) Life Sciences Investor Forum
6th Oct 20213:53 pmRNSPosting of Annual Report and Notice of AGM
30th Sep 202112:08 pmRNSHolding(s) in Company
29th Sep 20212:35 pmRNSHolding(s) in Company
17th Sep 20217:00 amRNSHardman & Co Life Sciences Investor Forum
16th Sep 202110:15 amEQSHardman & Co Research: Diurnal Group (DNL): All set for three pivotal trials
15th Sep 20219:17 amRNSDirector Dealings
14th Sep 20217:00 amRNSResults for the year ended 30 June 2021
13th Sep 20217:00 amRNSCommercial launch of Efmody in the UK
1st Sep 20217:00 amRNSDiurnal launches Efmody in Germany and Austria
19th Aug 20217:00 amRNSFull Year Results Investor Presentation
12th Aug 20217:20 amEQSHardman & Co Video Event | Diurnal Group plc - Investor Forum
2nd Aug 20217:00 amRNSGrant of Deferred Share Awards
28th Jul 20217:00 amRNSBusiness and Trading Update
14th Jul 20217:00 amRNSDirector Dealings
12th Jul 20217:00 amRNSAgreement from US FDA on SPA for Chronocort
9th Jul 20218:30 amRNSDirector Dealings and Issue of Equity
7th Jul 20217:00 amRNSNotice of Full Year Results
5th Jul 20217:00 amRNSShares and AJ Bell Investor Evening Webinar
2nd Jul 20217:00 amRNSMarketing Authorisation for Efmody in GB from MHRA
29th Jun 20217:00 amRNSDistribution agreement with Er-Kim
2nd Jun 202112:19 pmRNSDirector Dealings
1st Jun 20217:00 amRNSDiurnal triggers milestone payments from Citrine
28th May 20212:33 pmRNSEuropean Commission approval received for Efmody
13th May 20217:00 amRNSCorrection: Director Dealings
12th May 20215:32 pmRNSDirector Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.